<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01751906</url>
  </required_header>
  <id_info>
    <org_study_id>10-392</org_study_id>
    <nct_id>NCT01751906</nct_id>
  </id_info>
  <brief_title>ABSORB III Randomized Controlled Trial (RCT)</brief_title>
  <acronym>ABSORB-III</acronym>
  <official_title>A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ABSORB III RCT is a prospective randomized, single-blind, multi-center trial. It is the
      pivotal trial to support the US pre-market approval (PMA) of Absorb™ Bioresorbable Vascular
      Scaffold (BVS).

      The ABSORB III includes additional two trials i.e. ABSORB III PK (pharmacokinetics) sub-study
      and ABSORB IV RCT trial which are maintained under one protocol because both trial designs
      are related, ABSORB IV is the continuation of ABSORB III and the data from ABSORB III and
      ABSORB IV will be pooled to support the ABSORB IV primary endpoint. Both the trials will
      evaluate the safety and effectiveness of Absorb BVS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ABSORB III RCT:

      A. Primary Objective: The pivotal trial to support the US pre-market approval (PMA) of Absorb
      BVS. ABSORB III will evaluate the safety and effectiveness of the Absorb BVS System compared
      to the XIENCE in the treatment of subjects, including those with diabetes mellitus, with
      ischemic heart disease caused by up to two de novo native coronary artery lesions in separate
      epicardial vessels.

      B. Powered Secondary Objectives:

        1. Lead-In Phase Objective: To evaluate the applicability and transferability of the
           didactic Absorb BVS physician training plan to US clinical practice.

           The lead-in phase is a non-randomized, single-arm, open label group of up to 50 subjects
           treated with Absorb BVS at up to 35 US sites. The Lead-In phase will enroll/register
           subjects prior to the randomization phase of ABSORB III.

           The Lead-In Phase allows the treatment of up to two de novo native coronary artery
           lesions in different epicardial vessels with reference vessel diameter (RVD) ≥ 2.75 mm
           to ≤ 3.25 mm and lesion lengths ≥ 8 to ≤ 14 mm.

        2. Imaging Cohort Objective: To evaluate long-term vascular function and patency of the
           Absorb BVS treated segments compared to XIENCE treated segments in the treatment of
           subjects with ischemic heart disease caused by up to two de novo native coronary artery
           lesions in separate epicardial vessels.

      The imaging cohort-phase is a prospective, randomized (2:1 Absorb BVS to XIENCE),
      single-blind, multi-center trial, registering approximately 200 subjects. This includes 150
      subjects for the angiographic/intravascular ultrasound (IVUS) endpoints analysis and
      approximately 50 subjects for optical coherence tomography (OCT) endpoints analysis. The 200
      subjects are separate from the 2000 subjects included in the primary analysis. Data from two
      powered secondary endpoints from this cohort will support label claims of superiority of
      Absorb BVS as compared to XIENCE specific to vasomotion and late lumen enlargement.

      All other subjects in ABSORB III unless specified will receive treatment of up to two de novo
      native coronary artery lesions in different epicardial vessels with RVD ≥ 2.5 mm to ≤ 3.75 mm
      and lesion lengths ≤ 24 mm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TV-MI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Success- Device Success (Lesion Level Analysis)</measure>
    <time_frame>On day 0 (the day of procedure)</time_frame>
    <description>Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Success: Procedural Success (Subject Level Analysis)</measure>
    <time_frame>On day 0 (the day of procedure)</time_frame>
    <description>Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Powered Secondary Endpoint: Angina</measure>
    <time_frame>1 year</time_frame>
    <description>Angina is defined as the first adverse event resulting in the site diagnosis of angina.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Powered Secondary Endpoint: Ischemia Driven Target Vessel Revascularization (ID-TVR)</measure>
    <time_frame>1 year</time_frame>
    <description>This powered secondary endpoint is intended to assess all ID-TVR at 1 year and test for superiority of Absorb BVS to XIENCE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>DEATH (Per Academic Research Consortium (ARC)) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>4 years</time_frame>
    <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>5 years</time_frame>
    <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>4 years</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>5 years</time_frame>
    <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>4 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>5 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
Target Vessel Revascularization (TVR,) excluding TLR includes:
ID-TVR excluding TLR.
Non-ID TVR excluding TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
Target Vessel Revascularization (TVR,) excluding TLR includes:
ID-TVR excluding TLR.
Non-ID TVR excluding TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
Target Vessel Revascularization (TVR,) excluding TLR includes:
ID-TVR excluding TLR.
Non-ID TVR excluding TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
Target Vessel Revascularization (TVR,) excluding TLR includes:
ID-TVR excluding TLR.
Non-ID TVR excluding TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</measure>
    <time_frame>4 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</measure>
    <time_frame>5 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularization</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularization</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularization</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Powered Secondary Endpoint: All Revascularization</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>This powered secondary endpoint is intended to assess all revascularization at 1 year and test for superiority of Absorb BVS to XIENCE. All revascularizations are comprised of TLR, TVR excluding TLR, and non-TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularization</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularization</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularization</measure>
    <time_frame>4 years</time_frame>
    <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularization</measure>
    <time_frame>5 years</time_frame>
    <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>4 years</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI</measure>
    <time_frame>5 years</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>4 years</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>5 years</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>4 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>5 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>4 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>5 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>4 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF)</measure>
    <time_frame>5 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>4 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>5 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Stent/Scaffold Thrombosis (Per ARC Definition)</measure>
    <time_frame>≤ 1 Day</time_frame>
    <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute/Subacute Stent/Scaffold Thrombosis (Per ARC Definition)</measure>
    <time_frame>0 to 30 Days</time_frame>
    <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Subacute Stent/Scaffold Thrombosis</measure>
    <time_frame>&gt;1 to 30 Days</time_frame>
    <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent/Scaffold Thrombosis (Per ARC Definition)</measure>
    <time_frame>759 to 1123 days</time_frame>
    <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of Any unexplained death within the first 30 days or Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent/Scaffold Thrombosis (Per ARC Definition)</measure>
    <time_frame>394 to 1123 days</time_frame>
    <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of Any unexplained death within the first 30 days or Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Late Stent/Scaffold Thrombosis (Per ARC Definition)</measure>
    <time_frame>31 to 365 Days</time_frame>
    <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)</measure>
    <time_frame>4 years</time_frame>
    <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of Any unexplained death within the first 30 days or Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)</measure>
    <time_frame>5 years</time_frame>
    <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of Any unexplained death within the first 30 days or Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Very Late Stent /Scaffold Thrombosis (Per ARC Definition)</measure>
    <time_frame>366 to 393 Days</time_frame>
    <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cumulative Stent/Scaffold Thrombosis (Per ARC Definition)</measure>
    <time_frame>0 to 393 Days</time_frame>
    <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cumulative Stent/Scaffold Thrombosis</measure>
    <time_frame>0 to 758 Days</time_frame>
    <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cumulative Stent/Scaffold Thrombosis</measure>
    <time_frame>0 to 1123 Days</time_frame>
    <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-Procedure Minimum Lumen Diameter (MLD)</measure>
    <time_frame>&lt; or = 1 day</time_frame>
    <description>Angiographic endpoint Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-Procedure Percent Diameter Stenosis (%DS)</measure>
    <time_frame>&lt; or = 1 day</time_frame>
    <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Procedure In-Segment Minimum Lumen Diameter (MLD)</measure>
    <time_frame>≤ 7 days post index procedure</time_frame>
    <description>Angiographic endpoint. Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen.
In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Procedure In-Device Minimum Lumen Diameter (MLD)</measure>
    <time_frame>≤ 7 days post index procedure</time_frame>
    <description>Angiographic endpoint. Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen.
In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Procedure In-Segment Percent Diameter Stenosis (%DS)</measure>
    <time_frame>≤ 7 days post index procedure</time_frame>
    <description>Angiographic endpoint. Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).
In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Procedure In-Device Percent Diameter Stenosis (%DS)</measure>
    <time_frame>≤ 7 days post index procedure</time_frame>
    <description>Angiographic endpoint. Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Powered Imaging Cohort Secondary Endpoint: The In-stent/Scaffold Mean Lumen Diameter Change, Between Pre- and Post-nitrate Infusion at 3 Years by Angiography</measure>
    <time_frame>3 years</time_frame>
    <description>Pooled angiographic subjects (~600 subjects): 200 subjects from the Imaging Cohort of ABSORB III and 400 subjects from the ABSORB Japan RCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Powered Imaging Cohort Secondary Endpoint: The In-stent/Scaffold Mean Lumen Area Change, From Post-procedure to 3 Years by Intravascular Ultrasound (IVUS)</measure>
    <time_frame>3 years</time_frame>
    <description>Mean lumen area measured after nitrate infusions, superiority test, ~300 pooled subjects.
Pooled IVUS subjects (~300 subjects): 150 subjects from the Imaging Cohort of ABSORB III RCT and 150 subjects from ABSORB Japan RCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical Coherence Tomography (OCT) Endpoint</measure>
    <time_frame>3 years</time_frame>
    <description>All OCT endpoints will be collected for within the device and within the treated segment:
Descriptive analysis of strut, lesion and vessel morphology Mean neointimal area (NIA) - Apposed to the vessel wall with neointimal coverage Apposed to vessel wall without neointimal coverage Incomplete apposition to vessel wall with neointimal coverage Incomplete apposition to vessel wall without neointimal coverage Lumen area/volume stenosis % Mean/minimal device area Mean/minimal luminal area/volume Mean strut area/volume Persisting incomplete apposition, late incomplete apposition at 3 years (if analyzable) OCT analysis for subjects with jailed side branch Descriptive analyses from 3-dimensional OCT reconstructions</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO): Overall Health Status</measure>
    <time_frame>Baseline</time_frame>
    <description>Overall health status assessed using the EuroQoL 5D (EQ-5D™).
EQ-5D:
Scale range: 0 to 1
Higher values represent better outcomes
Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Subscale scores are summed to obtain total/overall health status.
A scoring algorithm was used to combine the sub-scores from each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), and generate a single index ranging from 0 to 1</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO): Overall Health Status</measure>
    <time_frame>1 month</time_frame>
    <description>Overall health status assessed using the EuroQoL 5D (EQ-5D™).
EQ-5D:
Scale range: 0 to 1
Higher values represent better outcomes
Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Subscale scores are summed to obtain total/overall health status.
A scoring algorithm was used to combine the sub-scores from each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), and generate a single index ranging from 0 to 1</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO): Overall Health Status</measure>
    <time_frame>12 months</time_frame>
    <description>Overall health status assessed using the EuroQoL 5D (EQ-5D™).
EQ-5D:
Scale range: 0 to 1
Higher values represent better outcomes
Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Subscale scores are summed to obtain total/overall health status.
A scoring algorithm was used to combine the sub-scores from each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), and generate a single index ranging from 0 to 1</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO): Anxiety</measure>
    <time_frame>Baseline</time_frame>
    <description>Anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7).
GAD-7:
Scale range: 0 to 21
Lower values represent better outcomes
No subscales</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO): Anxiety</measure>
    <time_frame>1 month</time_frame>
    <description>Anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7).
GAD-7:
Scale range: 0 to 21
Lower values represent better outcomes
No subscales</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO): Anxiety</measure>
    <time_frame>12 months</time_frame>
    <description>Anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7).
GAD-7:
Scale range: 0 to 21
Lower values represent better outcomes
No subscales</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO): Disease-Specific Quality of Life</measure>
    <time_frame>Baseline</time_frame>
    <description>Disease-Specific quality of life assessed using the Seattle Angina Questionnaire (SAQ)
Seattle Angina Questionnaire (SAQ): Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO): Disease-Specific Quality of Life</measure>
    <time_frame>1 month</time_frame>
    <description>Disease-Specific quality of life in hospital baseline and at 1 year assessed using the Seattle Angina Questionnaire (SAQ).
Seattle Angina Questionnaire (SAQ): Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO): Disease-Specific Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Disease-Specific quality of life in hospital baseline and at 1 year assessed using the Seattle Angina Questionnaire (SAQ).
Seattle Angina Questionnaire (SAQ): Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO): Dyspnea Severity</measure>
    <time_frame>Baseline</time_frame>
    <description>Dyspnea severity assessed using the Rose Dyspnea Scale (RDS).
Rose Dyspnea Scale:
Scale range: 0 to 4
Lower values represent better outcomes (higher scores indicate worse dyspnea)
No subscales</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO): Dyspnea Severity</measure>
    <time_frame>1 month</time_frame>
    <description>Dyspnea severity assessed using the Rose Dyspnea Scale (RDS).
Rose Dyspnea Scale:
Scale range: 0 to 4
Lower values represent better outcomes (higher scores indicate worse dyspnea)
No subscales</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO): Dyspnea Severity</measure>
    <time_frame>12 months</time_frame>
    <description>Dyspnea severity assessed using the Rose Dyspnea Scale (RDS).
Rose Dyspnea Scale:
Scale range: 0 to 4
Lower values represent better outcomes (higher scores indicate worse dyspnea)
No subscales</description>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on TLF and Components</measure>
    <time_frame>3-4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on TLF and Components</measure>
    <time_frame>3-5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on TLF and Components</measure>
    <time_frame>3-6 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on TLF and Components</measure>
    <time_frame>3-7 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on TLF and Components</measure>
    <time_frame>3-8 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on TLF and Components</measure>
    <time_frame>3-9 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on TLF and Components</measure>
    <time_frame>3-10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</measure>
    <time_frame>3-4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</measure>
    <time_frame>3-5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</measure>
    <time_frame>3-6 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</measure>
    <time_frame>3-7 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</measure>
    <time_frame>3-8 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</measure>
    <time_frame>3-9 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</measure>
    <time_frame>3-10 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2008</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>Absorb BVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving Absorb BVS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XIENCE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Absorb BVS</intervention_name>
    <description>Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
    <arm_group_label>Absorb BVS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE</intervention_name>
    <description>Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
    <arm_group_label>XIENCE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          1. 18 years of age.

          2. Subject or a legally authorized representative must provide written Informed Consent
             prior to any study related procedure, per site requirements.

          3. Subject must have evidence of myocardial ischemia. In the absence of noninvasive
             ischemia, fractional flow reserve (FFR) must be done and indicative of ischemia.

          4. Acceptable candidate for coronary artery bypass graft (CABG) surgery.

          5. Female subject of childbearing potential who does not plan pregnancy for up to 1 year
             following the index procedure. For a female subject of childbearing potential a
             pregnancy test must be performed with negative results known within 7 days prior to
             the index procedure per site standard.

          6. Female subject is not breast-feeding at the time of the screening visit and will not
             be breast-feeding for up to 1 year following the index procedure.

          7. Subject agrees to not participate in any other investigational or invasive clinical
             study for a period of 1 year following the index procedure.

        General Exclusion Criteria:

          1. Any surgery requiring general anesthesia or discontinuation of aspirin and/or an
             adenosine diphosphate (ADP) antagonist is planned within 12 months after the
             procedure.

          2. Hypersensitivity or contraindication to device material and its degradants
             (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and cobalt,
             chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be
             adequately pre-medicated. Subject has a known contrast sensitivity that cannot be
             adequately pre-medicated.

          3. Allergic reaction, hypersensitivity or contraindication to aspirin; or to clopidogrel
             and prasugrel and ticagrelor; or to heparin and bivalirudin, and therefore cannot be
             adequately treated with study medications.

          4. Acute myocardial infarction (AMI: STEMI or NSTEMI) within 72 hours of the index
             procedure and both creatine kinase (CK) and CK-MB have not returned to within normal
             limits at the time of index procedure; or subject with stable angina or silent
             ischemia has CK-MB that is greater than normal limits at the time of the index
             procedure.

          5. Subject is currently experiencing clinical symptoms consistent with new onset AMI
             (STEMI or NSTEMI), such as nitrate-unresponsive prolonged chest pain with ischemic ECG
             changes.

          6. Cardiac arrhythmia as identified at the time of screening for which at least one of
             the following criteria is met:

             (NOTE: Investigator should use discretion when enrolling subjects with high CHADS
             scores)

               1. Subject requires coumadin or any other agent for chronic oral anticoagulation

               2. Subject is likely to become hemodynamically unstable due to their arrhythmia

               3. Subject has poor survival prognosis due to their arrhythmia

          7. Left ventricular ejection fraction (LVEF) &lt; 30%.

          8. Subject has undergone prior percutaneous coronary intervention (PCI) within the target
             vessel during the last 12 months. Prior PCI within the non-target vessel or any
             peripheral intervention is acceptable if performed anytime &gt;30 days before the index
             procedure, or between 24 hours and 30 days before the index procedure if successful
             and uncomplicated.

          9. Future staged PCI either in target or non-target vessels or subject requires future
             peripheral interventions &lt; 30 days after the index procedure.

         10. Subject has received any solid organ transplants or is on a waiting list for any solid
             organ transplants.

         11. At the time of screening, the subject has a malignancy that is not in remission.

         12. Subject is receiving immunosuppressant therapy or has known immunosuppressive or
             severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human
             immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are
             not included as immunosuppressant therapy.

         13. Subject has previously received or is scheduled to receive radiotherapy to a coronary
             artery (vascular brachytherapy), or the chest/mediastinum.

         14. Subject is receiving or will require chronic anticoagulation therapy (e.g., coumadin,
             dabigatran, apixaban, rivaroxaban or any other agent for any reason).

         15. Subject has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3.

         16. Subject has a documented or suspected hepatic disorder as defined as cirrhosis or
             Child-Pugh ≥ Class B.

         17. Renal insufficiency. NOTE: Estimated glomerular filtration rate (GFR) can be based on
             Modification of Diet in Renal Disease (MDRD) equation or Cockcroft-Gault equation
             (CCG).

         18. High risk of bleeding for any reason; has a history of bleeding diathesis or
             coagulopathy; has had a significant gastro-intestinal or significant urinary bleed
             within the past six months.

         19. Cerebrovascular accident or transient ischemic neurological attack (TIA) within the
             past six months, or any prior intracranial bleed, or any permanent neurologic defect,
             or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation,
             etc.).

         20. Extensive peripheral vascular disease that precludes safe 6 French sheath insertion.
             Note: femoral arterial disease does not exclude the patient if radial access may be
             used.

         21. Subject has life expectancy &lt; 5 years for any non-cardiac cause or cardiac cause.

         22. Subject is in the opinion of the Investigator or designee, unable to comply with the
             requirements of the study protocol or is unsuitable for the study for any reason. This
             includes completion of Patient Reported Outcome instruments.

         23. Subject is currently participating in another clinical trial that has not yet
             completed its primary endpoint.

         24. Vulnerable population.

        Angiographic Inclusion Criteria:

          1. One or two de novo target lesions:

               1. If there is one target lesion, a second non-target lesion may be treated but the
                  non-target lesion must be present in a different epicardial vessel, and must be
                  treated first with a successful, uncomplicated result prior to randomization of
                  the target lesion.

               2. If two target lesions are present, they must be present in different epicardial
                  vessels and both must satisfy the angiographic eligibility criteria.

               3. The definition of epicardial vessels means the LAD, LCX and RCA and their
                  branches. Thus, the patient must not have lesions requiring treatment in e.g.
                  both the LAD and a diagonal branch.

          2. Target lesion(s) must be located in a native coronary artery with a visually estimated
             or quantitatively assessed % diameter stenosis (DS) of ≥ 50% and &lt; 100% with a
             thrombolysis in myocardial infarction (TIMI) flow of ≥1 and one of the following:
             stenosis ≥ 70%, an abnormal functional test (e.g. fractional flow reserve, stress
             test), unstable angina or post-infarct angina.

               1. Lesion(s) must be located in a native coronary artery with RVD by visual
                  estimation of ≥ 2.5 mm and ≤ 3.75 mm.

               2. Lesion(s) must be located in a native coronary artery with length by visual
                  estimation of ≤ 24 mm.

               3. For Lead-In subjects with 3.0x18 mm Absorb BVS: lesion(s) must be located in a
                  native coronary artery with RVD by visual estimation of ≥ 2.75 mm and ≤ 3.25 mm.
                  The lesion length by visual estimation is ≥ 8 mm and ≤ 14 mm.

        Angiographic Exclusion Criteria:

        All exclusion criteria apply to the target lesion(s) or target vessel(s).

          1. Lesion which prevents successful balloon pre-dilatation, defined as full balloon
             expansion with the following outcomes:

               1. Residual %DS is a maximum of &lt; 40% (per visual estimation), ≤ 20% is strongly
                  recommended.

               2. TIMI Grade-3 flow (per visual estimation).

               3. No angiographic complications (e.g. distal embolization, side branch closure).

               4. No dissections National Heart Lung and Blood Institute (NHLBI) grade D-F.

               5. No chest pain lasting &gt; 5 minutes.

               6. No ST depression or elevation lasting &gt; 5 minutes

          2. Lesion is located in left main.

          3. Aorto-ostial right coronary artery (RCA) lesion (within 3 mm of the ostium).

          4. Lesion located within 3 mm of the origin of the Left Anterior Descending Artery (LAD)
             or left circumflex artery (LCX).

          5. Lesion involving a bifurcation with a:

               1. side branch ≥ 2 mm in diameter, or

               2. side branch with either an ostial or non-ostial lesion with diameter stenosis &gt;
                  50%, or

               3. side branch requiring dilatation.

          6. Anatomy proximal to or within the lesion that may impair delivery of the Absorb BVS or
             XIENCE stent:

               1. Extreme angulation (≥ 90°) proximal to or within the target lesion.

               2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.

               3. Moderate or heavy calcification proximal to or within the target lesion. If IVUS
                  used, subject must be excluded if calcium arc in the vessel prior to the lesion
                  or within the lesion is ≥ 180°.

          7. Vessel contains thrombus as indicated in the angiographic images or by IVUS or OCT.

          8. Lesion or vessel involves a myocardial bridge.

          9. Vessel has been previously treated with a stent at any time prior to the index
             procedure such that the Absorb BVS or XIENCE would need to cross the stent to reach
             the target lesion.

         10. Vessel has been previously treated and the target lesion is within 5 mm proximal or
             distal to a previously treated lesion.

         11. Target lesion located within an arterial or saphenous vein graft or distal to any
             arterial or saphenous vein graft.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen G Ellis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic, Cleveland OH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dean J Kereiakes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christ Hospital, Cincinnati, OH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregg W Stone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University Medical Center, New York, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer McMeans Jones</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Medical Devices</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baptist Medical Center Princeton</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Hospital</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center South</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chandler Regional Medical Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Heart Hospital</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Good Samaritan Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Muir Medical Center - Concord Campus</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Memorial Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Central Valley Hospitals dba Memorial Medical Center</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Cottage Hospital</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Company Of Mary Hospital</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Memorial Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Rockies</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Medical Center</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brandon Regional Hospital</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center - Downtown</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida UF Health</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munroe Regional Medical Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Gardens Medical Center</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay County Health Systems</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial Hospital</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Pepin Heart Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Hospital-Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellstar Kennestone Hospital</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart General Healthcare</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan St. Francis Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Medical Center</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Hospital and Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Memorial Hospital</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Regional Medical Center</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center of Boston</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Regional Medical Center</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakwood Hospital and Medical Center</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harper University Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Hospital &amp; Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sparrow Hospital</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Hospital</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munson Medical Center</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Memorial Medical Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center Cardiology Associates Research, LLC</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boone Hospital Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anthony's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Patrick Hospital</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Hospital</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Englewood Hospital and Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <zip>08035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of Lourdes Medical Center</name>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <zip>08035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jersey Shore University Medical Center</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Regional Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital Health Center</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital-Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strong Memorial Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14627</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center - Pineville</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rex Hospital</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Health Good Samaritan Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda North Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMH Healthcare</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Cln Fairview Hospital</name>
      <address>
        <city>Fairview Park</city>
        <state>Ohio</state>
        <zip>44126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kettering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy St. Vincent's Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis-Good Samaritan Hospital</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integris Baptist Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Medical Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PeaceHealth Sacred Heart Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Spirit Hospital</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doylestown Hospital</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hamot</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary Medical Center</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forbes Hospital</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Shadyside Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health at Harrisburg Hospital</name>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AnMed Health</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sisters of Charity Providence Hospital</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Memorial Hospital of the Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont Holston Valley Medical Center</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turkey Creek Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Texas Healthcare System</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Medical Center Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Texsan Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Texas Medical Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Mother Frances Hospital Regional Healthcare Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InterMountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Washington Hospital</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Roanoke Memorial Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winchester Medical Center</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Regional Medical Center Everett</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2012</study_first_posted>
  <results_first_submitted>August 29, 2017</results_first_submitted>
  <results_first_submitted_qc>January 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2018</results_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Absorb™ BVS</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Bioabsorbable</keyword>
  <keyword>BVS</keyword>
  <keyword>Bioresorbable</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Artery Endothelial Responsiveness</keyword>
  <keyword>Coronary artery restenosis</keyword>
  <keyword>Coronary artery stenosis</keyword>
  <keyword>Coronary scaffold</keyword>
  <keyword>Coronary Stent</keyword>
  <keyword>Drug eluting stents</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Myocardial ischemia</keyword>
  <keyword>Stent thrombosis</keyword>
  <keyword>Stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first Lead-In subject (Lead-In Group ) was registered on Dec 28, 2012. A total of 2008 patients (Primary Analysis Group) were randomized into Absorb BVS arm (n = 1322) and Xience arm (n = 686) at 193 study sites between 22 March 2013 &amp; 3 April 2014 and the last 3 year follow-up visit was on August 28,2017.</recruitment_details>
      <pre_assignment_details>Of total 13,789 eligible population,11,781 patients were excluded due to,
Not meeting general eligibility criteria only (n=567);
Not meeting angiographic eligibility criteria only (n=10,690);
Not meeting both 1 and 2 (n=64);
Other reasons (n=460).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Absorb BVS</title>
          <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
        </group>
        <group group_id="P2">
          <title>XIENCE</title>
          <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1322"/>
                <participants group_id="P2" count="686"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1238"/>
                <participants group_id="P2" count="639"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Absorb BVS</title>
          <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
        </group>
        <group group_id="B2">
          <title>XIENCE</title>
          <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1322"/>
            <count group_id="B2" value="686"/>
            <count group_id="B3" value="2008"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="10.6"/>
                    <measurement group_id="B2" value="63.6" spread="10.3"/>
                    <measurement group_id="B3" value="63.5" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="388"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="593"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="934"/>
                    <measurement group_id="B2" value="481"/>
                    <measurement group_id="B3" value="1415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1322"/>
                    <measurement group_id="B2" value="686"/>
                    <measurement group_id="B3" value="2008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension Requiring Medication</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1071"/>
                    <measurement group_id="B2" value="553"/>
                    <measurement group_id="B3" value="1624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dyslipidemia Requiring Medication</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1009"/>
                    <measurement group_id="B2" value="533"/>
                    <measurement group_id="B3" value="1542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Coronary Intervention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="512"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stable Angina</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="757"/>
                    <measurement group_id="B2" value="417"/>
                    <measurement group_id="B3" value="1174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TV-MI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>1 year</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TV-MI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
                <count group_id="O2" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Success- Device Success (Lesion Level Analysis)</title>
        <description>Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.</description>
        <time_frame>On day 0 (the day of procedure)</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Success- Device Success (Lesion Level Analysis)</title>
          <description>Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of lesions</units>
          <param>Number</param>
          <units_analyzed>Target Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1311"/>
                <count group_id="O2" value="678"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1355"/>
                <count group_id="O2" value="704"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                    <measurement group_id="O2" value="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Success: Procedural Success (Subject Level Analysis)</title>
        <description>Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).</description>
        <time_frame>On day 0 (the day of procedure)</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Success: Procedural Success (Subject Level Analysis)</title>
          <description>Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1311"/>
                <count group_id="O2" value="678"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1240"/>
                    <measurement group_id="O2" value="652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Powered Secondary Endpoint: Angina</title>
        <description>Angina is defined as the first adverse event resulting in the site diagnosis of angina.</description>
        <time_frame>1 year</time_frame>
        <population>The analysis will exclude angina following the index procedure through discharge, not to exceed a period of 7 days. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Powered Secondary Endpoint: Angina</title>
          <description>Angina is defined as the first adverse event resulting in the site diagnosis of angina.</description>
          <population>The analysis will exclude angina following the index procedure through discharge, not to exceed a period of 7 days. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1303"/>
                <count group_id="O2" value="678"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9256</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Powered Secondary Endpoint: Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
        <description>This powered secondary endpoint is intended to assess all ID-TVR at 1 year and test for superiority of Absorb BVS to XIENCE.</description>
        <time_frame>1 year</time_frame>
        <population>For ID-TVR, Fisher’s exact test is used for superiority testing based on the ITT population. This analysis will include ~2000 subjects. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Powered Secondary Endpoint: Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
          <description>This powered secondary endpoint is intended to assess all ID-TVR at 1 year and test for superiority of Absorb BVS to XIENCE.</description>
          <population>For ID-TVR, Fisher’s exact test is used for superiority testing based on the ITT population. This analysis will include ~2000 subjects. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
                <count group_id="O2" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2126</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>DEATH (Per Academic Research Consortium (ARC)) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>DEATH (Per Academic Research Consortium (ARC)) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1319"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1317"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 180 days</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1315"/>
                <count group_id="O2" value="681"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
                <count group_id="O2" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1296"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>DEATH (Per ARC Circulation) : All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>5 years</time_frame>
        <posting_date>05/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1319"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>0 to 30 days</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1317"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>0 to 180 days</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1315"/>
                <count group_id="O2" value="681"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
                <count group_id="O2" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1296"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>5 years</time_frame>
        <posting_date>05/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1319"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1317"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
        <time_frame>0 to 180 days</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1315"/>
                <count group_id="O2" value="681"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
                <count group_id="O2" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1296"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
        <time_frame>4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven (ID-TLR) or not ischemia driven (NID-TLR) by the investigator prior to repeat angiography.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
        <time_frame>5 years</time_frame>
        <posting_date>05/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
Target Vessel Revascularization (TVR,) excluding TLR includes:
ID-TVR excluding TLR.
Non-ID TVR excluding TLR.</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
Target Vessel Revascularization (TVR,) excluding TLR includes:
ID-TVR excluding TLR.
Non-ID TVR excluding TLR.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1319"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
Target Vessel Revascularization (TVR,) excluding TLR includes:
ID-TVR excluding TLR.
Non-ID TVR excluding TLR.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
Target Vessel Revascularization (TVR,) excluding TLR includes:
ID-TVR excluding TLR.
Non-ID TVR excluding TLR.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1317"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
Target Vessel Revascularization (TVR,) excluding TLR includes:
ID-TVR excluding TLR.
Non-ID TVR excluding TLR.</description>
        <time_frame>0 to 180 days</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
Target Vessel Revascularization (TVR,) excluding TLR includes:
ID-TVR excluding TLR.
Non-ID TVR excluding TLR.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1315"/>
                <count group_id="O2" value="681"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
Target Vessel Revascularization (TVR,) excluding TLR includes:
ID-TVR excluding TLR.
Non-ID TVR excluding TLR.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
Target Vessel Revascularization (TVR,) excluding TLR includes:
ID-TVR excluding TLR.
Non-ID TVR excluding TLR.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
                <count group_id="O2" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1296"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>5 years</time_frame>
        <posting_date>05/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularization</title>
        <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularization</title>
          <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1319"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularization</title>
        <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularization</title>
          <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1317"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularization</title>
        <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
        <time_frame>0 to 180 days</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularization</title>
          <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1315"/>
                <count group_id="O2" value="681"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Powered Secondary Endpoint: All Revascularization</title>
        <description>This powered secondary endpoint is intended to assess all revascularization at 1 year and test for superiority of Absorb BVS to XIENCE. All revascularizations are comprised of TLR, TVR excluding TLR, and non-TVR.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through 1 year without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Powered Secondary Endpoint: All Revascularization</title>
          <description>This powered secondary endpoint is intended to assess all revascularization at 1 year and test for superiority of Absorb BVS to XIENCE. All revascularizations are comprised of TLR, TVR excluding TLR, and non-TVR.</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through 1 year without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
                <count group_id="O2" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5040</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularization</title>
        <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularization</title>
          <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1296"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularization</title>
        <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularization</title>
          <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularization</title>
        <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
        <time_frame>4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularization</title>
        <description>All revascularization endpoint is comprised of TLR, TVR excluding TLR, and non-TVR.</description>
        <time_frame>5 years</time_frame>
        <posting_date>05/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1319"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>0 to 30 days</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1317"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>0 to 180 days</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1315"/>
                <count group_id="O2" value="681"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
                <count group_id="O2" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1296"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>5 years</time_frame>
        <posting_date>05/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1319"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>0 to 30 days</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1317"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>0 to 180 days</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1315"/>
                <count group_id="O2" value="681"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
                <count group_id="O2" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1296"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>5 years</time_frame>
        <posting_date>05/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1319"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1317"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 180 days</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1315"/>
                <count group_id="O2" value="681"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 1 year</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
                <count group_id="O2" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 2 years</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1296"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 3 years</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>5 years</time_frame>
        <posting_date>05/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1319"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1317"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>0 to 180 days</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1315"/>
                <count group_id="O2" value="681"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-followup, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization,respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-followup, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization,respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
                <count group_id="O2" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>0 to 2 years</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1296"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>0 to 3 years</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>5 years</time_frame>
        <posting_date>05/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-followup,defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization,respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-followup,defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization,respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1319"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>0 to 30 days</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1317"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>0 to 180 days</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1315"/>
                <count group_id="O2" value="681"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population. Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any DMR event (all death, all MI (regardless of MI definition), all revascularization, respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
                <count group_id="O2" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1296"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>5 years</time_frame>
        <posting_date>05/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1319"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1317"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>0 to 180 days</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1315"/>
                <count group_id="O2" value="681"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
                <count group_id="O2" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1296"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT set. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>5 years</time_frame>
        <posting_date>05/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Stent/Scaffold Thrombosis (Per ARC Definition)</title>
        <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
        <time_frame>≤ 1 Day</time_frame>
        <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Stent/Scaffold Thrombosis (Per ARC Definition)</title>
          <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
          <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1320"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute/Subacute Stent/Scaffold Thrombosis (Per ARC Definition)</title>
        <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
        <time_frame>0 to 30 Days</time_frame>
        <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute/Subacute Stent/Scaffold Thrombosis (Per ARC Definition)</title>
          <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
          <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1315"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Subacute Stent/Scaffold Thrombosis</title>
        <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
        <time_frame>&gt;1 to 30 Days</time_frame>
        <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Subacute Stent/Scaffold Thrombosis</title>
          <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
          <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1315"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent/Scaffold Thrombosis (Per ARC Definition)</title>
        <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of Any unexplained death within the first 30 days or Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
        <time_frame>759 to 1123 days</time_frame>
        <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent/Scaffold Thrombosis (Per ARC Definition)</title>
          <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of Any unexplained death within the first 30 days or Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
          <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1238"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent/Scaffold Thrombosis (Per ARC Definition)</title>
        <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of Any unexplained death within the first 30 days or Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
        <time_frame>394 to 1123 days</time_frame>
        <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent/Scaffold Thrombosis (Per ARC Definition)</title>
          <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of Any unexplained death within the first 30 days or Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
          <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1238"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Late Stent/Scaffold Thrombosis (Per ARC Definition)</title>
        <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
        <time_frame>31 to 365 Days</time_frame>
        <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Late Stent/Scaffold Thrombosis (Per ARC Definition)</title>
          <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
          <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1294"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)</title>
        <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of Any unexplained death within the first 30 days or Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
        <time_frame>4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)</title>
        <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of Any unexplained death within the first 30 days or Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
        <time_frame>5 years</time_frame>
        <posting_date>05/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Very Late Stent /Scaffold Thrombosis (Per ARC Definition)</title>
        <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
        <time_frame>366 to 393 Days</time_frame>
        <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Very Late Stent /Scaffold Thrombosis (Per ARC Definition)</title>
          <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
          <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1294"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cumulative Stent/Scaffold Thrombosis (Per ARC Definition)</title>
        <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
        <time_frame>0 to 393 Days</time_frame>
        <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cumulative Stent/Scaffold Thrombosis (Per ARC Definition)</title>
          <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
          <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1297"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cumulative Stent/Scaffold Thrombosis</title>
        <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
        <time_frame>0 to 758 Days</time_frame>
        <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cumulative Stent/Scaffold Thrombosis</title>
          <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
          <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1269"/>
                <count group_id="O2" value="656"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cumulative Stent/Scaffold Thrombosis</title>
        <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
        <time_frame>0 to 1123 Days</time_frame>
        <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cumulative Stent/Scaffold Thrombosis</title>
          <description>Stent Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the Catheterization lab.
Timing :
Acute : 0 - 24 hours post stent implantation; Subacute : &gt;24 hours - 30 days post stent implantation; Late : 30 days - 1 year post stent implantation; Very late : &gt;1 year post stent implantation.
Evidence:
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Probable stent thrombosis is considered to have occurred after intracoronary stenting in case of
Any unexplained death within the first 30 days or
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.</description>
          <population>Analyzed population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Stent/Scaffold Thrombosis event. ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1244"/>
                <count group_id="O2" value="640"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-Procedure Minimum Lumen Diameter (MLD)</title>
        <description>Angiographic endpoint Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen.</description>
        <time_frame>&lt; or = 1 day</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-Procedure Minimum Lumen Diameter (MLD)</title>
          <description>Angiographic endpoint Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1322"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1380"/>
                <count group_id="O2" value="708"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.37"/>
                    <measurement group_id="O2" value="0.90" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-Procedure Percent Diameter Stenosis (%DS)</title>
        <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
        <time_frame>&lt; or = 1 day</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-Procedure Percent Diameter Stenosis (%DS)</title>
          <description>Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1322"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1380"/>
                <count group_id="O2" value="708"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.25" spread="12.48"/>
                    <measurement group_id="O2" value="65.90" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Procedure In-Segment Minimum Lumen Diameter (MLD)</title>
        <description>Angiographic endpoint. Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen.
In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.</description>
        <time_frame>≤ 7 days post index procedure</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Procedure In-Segment Minimum Lumen Diameter (MLD)</title>
          <description>Angiographic endpoint. Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen.
In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1322"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1374"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="0.41"/>
                    <measurement group_id="O2" value="2.14" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Procedure In-Device Minimum Lumen Diameter (MLD)</title>
        <description>Angiographic endpoint. Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen.
In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold</description>
        <time_frame>≤ 7 days post index procedure</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Procedure In-Device Minimum Lumen Diameter (MLD)</title>
          <description>Angiographic endpoint. Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen.
In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1322"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1373"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="0.40"/>
                    <measurement group_id="O2" value="2.49" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Procedure In-Segment Percent Diameter Stenosis (%DS)</title>
        <description>Angiographic endpoint. Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).
In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.</description>
        <time_frame>≤ 7 days post index procedure</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Procedure In-Segment Percent Diameter Stenosis (%DS)</title>
          <description>Angiographic endpoint. Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).
In- Segment is defined as, within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or scaffold.</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1322"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1374"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.04" spread="7.94"/>
                    <measurement group_id="O2" value="19.82" spread="8.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Procedure In-Device Percent Diameter Stenosis (%DS)</title>
        <description>Angiographic endpoint. Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
        <time_frame>≤ 7 days post index procedure</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Procedure In-Device Percent Diameter Stenosis (%DS)</title>
          <description>Angiographic endpoint. Percent Diameter Stenosis is defined as the value calculated as 100 * (1 - Minimum Luminal Diameter (MLD)/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1322"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1369"/>
                <count group_id="O2" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.62" spread="8.77"/>
                    <measurement group_id="O2" value="6.41" spread="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Powered Imaging Cohort Secondary Endpoint: The In-stent/Scaffold Mean Lumen Diameter Change, Between Pre- and Post-nitrate Infusion at 3 Years by Angiography</title>
        <description>Pooled angiographic subjects (~600 subjects): 200 subjects from the Imaging Cohort of ABSORB III and 400 subjects from the ABSORB Japan RCT.</description>
        <time_frame>3 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Powered Imaging Cohort Secondary Endpoint: The In-stent/Scaffold Mean Lumen Area Change, From Post-procedure to 3 Years by Intravascular Ultrasound (IVUS)</title>
        <description>Mean lumen area measured after nitrate infusions, superiority test, ~300 pooled subjects.
Pooled IVUS subjects (~300 subjects): 150 subjects from the Imaging Cohort of ABSORB III RCT and 150 subjects from ABSORB Japan RCT.</description>
        <time_frame>3 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Optical Coherence Tomography (OCT) Endpoint</title>
        <description>All OCT endpoints will be collected for within the device and within the treated segment:
Descriptive analysis of strut, lesion and vessel morphology Mean neointimal area (NIA) - Apposed to the vessel wall with neointimal coverage Apposed to vessel wall without neointimal coverage Incomplete apposition to vessel wall with neointimal coverage Incomplete apposition to vessel wall without neointimal coverage Lumen area/volume stenosis % Mean/minimal device area Mean/minimal luminal area/volume Mean strut area/volume Persisting incomplete apposition, late incomplete apposition at 3 years (if analyzable) OCT analysis for subjects with jailed side branch Descriptive analyses from 3-dimensional OCT reconstructions</description>
        <time_frame>3 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO): Overall Health Status</title>
        <description>Overall health status assessed using the EuroQoL 5D (EQ-5D™).
EQ-5D:
Scale range: 0 to 1
Higher values represent better outcomes
Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Subscale scores are summed to obtain total/overall health status.
A scoring algorithm was used to combine the sub-scores from each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), and generate a single index ranging from 0 to 1</description>
        <time_frame>Baseline</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes (PRO): Overall Health Status</title>
          <description>Overall health status assessed using the EuroQoL 5D (EQ-5D™).
EQ-5D:
Scale range: 0 to 1
Higher values represent better outcomes
Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Subscale scores are summed to obtain total/overall health status.
A scoring algorithm was used to combine the sub-scores from each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), and generate a single index ranging from 0 to 1</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1249"/>
                <count group_id="O2" value="651"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.2"/>
                    <measurement group_id="O2" value="0.77" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO): Overall Health Status</title>
        <description>Overall health status assessed using the EuroQoL 5D (EQ-5D™).
EQ-5D:
Scale range: 0 to 1
Higher values represent better outcomes
Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Subscale scores are summed to obtain total/overall health status.
A scoring algorithm was used to combine the sub-scores from each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), and generate a single index ranging from 0 to 1</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes (PRO): Overall Health Status</title>
          <description>Overall health status assessed using the EuroQoL 5D (EQ-5D™).
EQ-5D:
Scale range: 0 to 1
Higher values represent better outcomes
Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Subscale scores are summed to obtain total/overall health status.
A scoring algorithm was used to combine the sub-scores from each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), and generate a single index ranging from 0 to 1</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1231"/>
                <count group_id="O2" value="647"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.18"/>
                    <measurement group_id="O2" value="0.85" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO): Overall Health Status</title>
        <description>Overall health status assessed using the EuroQoL 5D (EQ-5D™).
EQ-5D:
Scale range: 0 to 1
Higher values represent better outcomes
Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Subscale scores are summed to obtain total/overall health status.
A scoring algorithm was used to combine the sub-scores from each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), and generate a single index ranging from 0 to 1</description>
        <time_frame>12 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes (PRO): Overall Health Status</title>
          <description>Overall health status assessed using the EuroQoL 5D (EQ-5D™).
EQ-5D:
Scale range: 0 to 1
Higher values represent better outcomes
Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Subscale scores are summed to obtain total/overall health status.
A scoring algorithm was used to combine the sub-scores from each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), and generate a single index ranging from 0 to 1</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1087"/>
                <count group_id="O2" value="567"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.20"/>
                    <measurement group_id="O2" value="0.83" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO): Anxiety</title>
        <description>Anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7).
GAD-7:
Scale range: 0 to 21
Lower values represent better outcomes
No subscales</description>
        <time_frame>Baseline</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes (PRO): Anxiety</title>
          <description>Anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7).
GAD-7:
Scale range: 0 to 21
Lower values represent better outcomes
No subscales</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1009"/>
                <count group_id="O2" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" spread="5.86"/>
                    <measurement group_id="O2" value="6.34" spread="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO): Anxiety</title>
        <description>Anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7).
GAD-7:
Scale range: 0 to 21
Lower values represent better outcomes
No subscales</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes (PRO): Anxiety</title>
          <description>Anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7).
GAD-7:
Scale range: 0 to 21
Lower values represent better outcomes
No subscales</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1067"/>
                <count group_id="O2" value="556"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="4.64"/>
                    <measurement group_id="O2" value="3.33" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO): Anxiety</title>
        <description>Anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7).
GAD-7:
Scale range: 0 to 21
Lower values represent better outcomes
No subscales</description>
        <time_frame>12 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes (PRO): Anxiety</title>
          <description>Anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7).
GAD-7:
Scale range: 0 to 21
Lower values represent better outcomes
No subscales</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="911"/>
                <count group_id="O2" value="482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" spread="4.99"/>
                    <measurement group_id="O2" value="4.04" spread="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO): Disease-Specific Quality of Life</title>
        <description>Disease-Specific quality of life assessed using the Seattle Angina Questionnaire (SAQ)
Seattle Angina Questionnaire (SAQ): Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).</description>
        <time_frame>Baseline</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes (PRO): Disease-Specific Quality of Life</title>
          <description>Disease-Specific quality of life assessed using the Seattle Angina Questionnaire (SAQ)
Seattle Angina Questionnaire (SAQ): Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1195"/>
                <count group_id="O2" value="617"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.67" spread="20.20"/>
                    <measurement group_id="O2" value="67.11" spread="19.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO): Disease-Specific Quality of Life</title>
        <description>Disease-Specific quality of life in hospital baseline and at 1 year assessed using the Seattle Angina Questionnaire (SAQ).
Seattle Angina Questionnaire (SAQ): Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes (PRO): Disease-Specific Quality of Life</title>
          <description>Disease-Specific quality of life in hospital baseline and at 1 year assessed using the Seattle Angina Questionnaire (SAQ).
Seattle Angina Questionnaire (SAQ): Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1131"/>
                <count group_id="O2" value="589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.10" spread="14.27"/>
                    <measurement group_id="O2" value="86.98" spread="14.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO): Disease-Specific Quality of Life</title>
        <description>Disease-Specific quality of life in hospital baseline and at 1 year assessed using the Seattle Angina Questionnaire (SAQ).
Seattle Angina Questionnaire (SAQ): Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).</description>
        <time_frame>12 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes (PRO): Disease-Specific Quality of Life</title>
          <description>Disease-Specific quality of life in hospital baseline and at 1 year assessed using the Seattle Angina Questionnaire (SAQ).
Seattle Angina Questionnaire (SAQ): Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1014"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.05" spread="13.91"/>
                    <measurement group_id="O2" value="86.42" spread="14.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO): Dyspnea Severity</title>
        <description>Dyspnea severity assessed using the Rose Dyspnea Scale (RDS).
Rose Dyspnea Scale:
Scale range: 0 to 4
Lower values represent better outcomes (higher scores indicate worse dyspnea)
No subscales</description>
        <time_frame>Baseline</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes (PRO): Dyspnea Severity</title>
          <description>Dyspnea severity assessed using the Rose Dyspnea Scale (RDS).
Rose Dyspnea Scale:
Scale range: 0 to 4
Lower values represent better outcomes (higher scores indicate worse dyspnea)
No subscales</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1242"/>
                <count group_id="O2" value="651"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="1.48"/>
                    <measurement group_id="O2" value="1.65" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO): Dyspnea Severity</title>
        <description>Dyspnea severity assessed using the Rose Dyspnea Scale (RDS).
Rose Dyspnea Scale:
Scale range: 0 to 4
Lower values represent better outcomes (higher scores indicate worse dyspnea)
No subscales</description>
        <time_frame>1 month</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes (PRO): Dyspnea Severity</title>
          <description>Dyspnea severity assessed using the Rose Dyspnea Scale (RDS).
Rose Dyspnea Scale:
Scale range: 0 to 4
Lower values represent better outcomes (higher scores indicate worse dyspnea)
No subscales</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1220"/>
                <count group_id="O2" value="636"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="1.24"/>
                    <measurement group_id="O2" value="0.88" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO): Dyspnea Severity</title>
        <description>Dyspnea severity assessed using the Rose Dyspnea Scale (RDS).
Rose Dyspnea Scale:
Scale range: 0 to 4
Lower values represent better outcomes (higher scores indicate worse dyspnea)
No subscales</description>
        <time_frame>12 months</time_frame>
        <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes (PRO): Dyspnea Severity</title>
          <description>Dyspnea severity assessed using the Rose Dyspnea Scale (RDS).
Rose Dyspnea Scale:
Scale range: 0 to 4
Lower values represent better outcomes (higher scores indicate worse dyspnea)
No subscales</description>
          <population>ITT population. The number of participants analyzed includes subjects who had available follow-up data at that time frame. The analysis excludes subjects who are truly lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1080"/>
                <count group_id="O2" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="1.26"/>
                    <measurement group_id="O2" value="0.99" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on TLF and Components</title>
        <time_frame>3-4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on TLF and Components</title>
        <time_frame>3-5 years</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on TLF and Components</title>
        <time_frame>3-6 years</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on TLF and Components</title>
        <time_frame>3-7 years</time_frame>
        <posting_date>12/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on TLF and Components</title>
        <time_frame>3-8 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on TLF and Components</title>
        <time_frame>3-9 years</time_frame>
        <posting_date>12/2024</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on TLF and Components</title>
        <time_frame>3-10 years</time_frame>
        <posting_date>12/2025</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</title>
        <time_frame>3-4 years</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</title>
        <time_frame>3-5 years</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</title>
        <time_frame>3-6 years</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</title>
        <time_frame>3-7 years</time_frame>
        <posting_date>12/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</title>
        <time_frame>3-8 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</title>
        <time_frame>3-9 years</time_frame>
        <posting_date>12/2024</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</title>
        <time_frame>3-10 years</time_frame>
        <posting_date>12/2025</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Absorb BVS</title>
          <description>Subjects receiving Absorb BVS
Absorb BVS: • Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
        </group>
        <group group_id="E2">
          <title>XIENCE</title>
          <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
XIENCE: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="660" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="335" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANAEMIA OF CHRONIC DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEPARIN-INDUCED THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MICROCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NORMOCHROMIC NORMOCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC TAMPONADE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONDUCTION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY OSTIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">DRESSLER'S SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PRINZMETAL ANGINA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SINUS ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TORSADE DE POINTES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>CYSTIC LYMPHANGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>AMAUROSIS FUGAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATARACT NUCLEAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GLAUCOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">POSTERIOR CAPSULE OPACIFICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RETINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">ABDOMINAL HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIABETIC GASTROPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ENTEROVESICAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ANGIODYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">HIATUS HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTESTINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ACHALASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PANCREATIC CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ABASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">CATHETER SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DEVICE OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DROWNING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DRUG INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PELVIC MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUDDEN CARDIAC DEATH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SURGICAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SYSTEMIC INFLAMMATORY RESPONSE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">GALLBLADDER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">HEPATIC LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY TO ARTHROPOD STING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTHRITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BRONCHITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATHETER SITE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATHETER SITE CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">HIV INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INFECTED SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">MENINGITIS ASEPTIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>METAPNEUMOVIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ORAL FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ORCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">PNEUMONIA ADENOVIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMONIA NECROTISING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PRIMARY ATYPICAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SEPSIS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SEPTIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPINAL CORD INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VIRAL LABYRINTHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANAEMIA POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC PROCEDURE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">CEREBRAL HAEMORRHAGE TRAUMATIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE TRAUMATIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COLON INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CYSTITIS RADIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">EXPOSURE TO TOXIC AGENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">FALL</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ILIOTIBIAL BAND SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IN-STENT ARTERIAL RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LIMB TRAUMATIC AMPUTATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MENISCUS LESION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MULTIPLE FRACTURES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MULTIPLE INJURIES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MUSCLE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PLAQUE SHIFT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST CONCUSSION SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ADHESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROCEDURAL DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">PROCEDURAL HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROCEDURAL VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FUME INHALATION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SEROMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">SNAKE BITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPLENIC RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>STERNAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">TRAUMATIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ULNA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WOUND EVISCERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BIOPSY LUNG</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE MB INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE SYSTOLIC INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC ENZYMES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC STRESS TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST SEGMENT ELEVATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEART RATE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OXYGEN CONSUMPTION INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LACTIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DUPUYTREN'S CONTRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FRACTURE NONUNION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>JOINT EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OSTEOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SACROILIITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPONDYLOLISTHESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TENDINOUS CONTRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VERTEBRAL FORAMINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-CELL LYMPHOMA STAGE IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BENIGN OVARIAN TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLADDER NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">BRAIN NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BREAST CANCER STAGE III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIFFUSE LARGE B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GLIOBLASTOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEAD AND NECK CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEAD AND NECK CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOPHARYNGEAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">LIP AND/OR ORAL CAVITY CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MENINGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">METASTASES TO LYMPH NODES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>METASTATIC MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>METASTATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OVARIAN EPITHELIAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SINONASAL PAPILLOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">SKIN CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER LIMITED STAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">URETERIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UTERINE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VULVAL CANCER STAGE 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ALTERED STATE OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARACHNOIDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COMPLICATED MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CUBITAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIABETIC NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GUILLAIN-BARRE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEMIPLEGIC MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOXIC-ISCHAEMIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LATERAL MEDULLARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUMBAR RADICULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MYELOMALACIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NEUROLOGICAL SYMPTOM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NYSTAGMUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RADICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPONDYLITIC MYELOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUBDURAL HYGROMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THALAMIC INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THROMBOTIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UNRESPONSIVE TO STIMULI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URAEMIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VERTEBRAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL ABUSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DELIRIUM TREMENS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, VISUAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FALLOPIAN TUBE CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PELVIC HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERVENTILATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MEDIASTINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NON-CARDIOGENIC PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRACHEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COLOSTOMY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HIP ARTHROPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>KNEE ARTHROPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LEG AMPUTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE REMOVAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NEPHRECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPINAL FUSION SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRANSURETHRAL PROSTATECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ACCELERATED HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>AORTIC INTRAMURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTERIAL SPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INADEQUATELY CONTROLLED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ILIAC ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MALIGNANT HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN STEAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VENOUS INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1140" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="576" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANAEMIA OF CHRONIC DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC DIATHESIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEPARIN-INDUCED THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LYMPHADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MICROCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NORMOCHROMIC NORMOCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPLENIC INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="323" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATRIAL HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATRIAL THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK LEFT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK RIGHT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">CARDIAC TAMPONADE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONDUCTION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY NO-REFLOW PHENOMENON</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY OSTIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CYANOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIASTOLIC DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DRESSLER'S SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEART VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERTROPHIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NODAL ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NODAL RHYTHM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PRINZMETAL ANGINA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SINUS ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SINUS ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TORSADE DE POINTES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRICUSPID VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIOVENOUS MALFORMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CYSTIC LYMPHANGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MYOTONIC DYSTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EUSTACHIAN TUBE OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MIXED DEAFNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TYMPANIC MEMBRANE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOGONADISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THYROID CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>AGE-RELATED MACULAR DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>AMAUROSIS FUGAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATARACT NUCLEAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EYE PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EYE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GAZE PALSY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GLAUCOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MACULAR FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POSTERIOR CAPSULE OPACIFICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SCLERAL DISCOLOURATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SCLERAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VISUAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RETINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ABDOMINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BARRETT'S OESOPHAGUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIABETIC GASTROPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DUODENITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ENTEROVESICAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EROSIVE OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ERUCTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FAECAL INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FAECES DISCOLOURED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FOOD POISONING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FUNCTIONAL GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ANGIODYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA ORAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INFREQUENT BOWEL MOVEMENTS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTESTINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MOUTH HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ACHALASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL FOOD IMPACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL SPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PANCREATIC CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PANCREATITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">PEPTIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROCTALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RECTAL PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TONGUE CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TONGUE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TOOTH SOCKET HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ABASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BREAST COMPLICATION ASSOCIATED WITH DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATHETER SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATHETER SITE RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATHETER SITE RELATED REACTION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATHETER SITE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DEVICE OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DROWNING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DRUG INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FACE OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FEELING COLD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">HERNIA PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LOCAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="220" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PELVIC MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUDDEN CARDIAC DEATH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SURGICAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SYSTEMIC INFLAMMATORY RESPONSE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GALLBLADDER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEPATIC LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEPATOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY TO ARTHROPOD STING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FOOD ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ABDOMINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ACUTE SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ACUTE TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS GRAFT SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTHRITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BACTERIAL DISEASE CARRIER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BREAST ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BRONCHITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARBUNCLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATHETER SITE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATHETER SITE CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EYELID INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FURUNCLE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GROIN ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HELICOBACTER INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEPATITIS C</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER OPHTHALMIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HIV INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">IMPLANT SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INFECTED SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MENINGITIS ASEPTIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>METAPNEUMOVIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ONYCHOMYCOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ORAL FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ORCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OTITIS EXTERNA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PILONIDAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ADENOVIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">PNEUMONIA NECROTISING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PRIMARY ATYPICAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROSTATE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SEPSIS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SEPTIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPINAL CORD INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TINEA PEDIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VIRAL LABYRINTHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANAEMIA POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANIMAL BITE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANXIETY POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTHROPOD STING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>AVULSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BURNS THIRD DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC PROCEDURE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE TRAUMATIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COLON INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORNEAL ABRASION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY RESTENOSISv</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CYSTITIS RADIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">DEEP VEIN THROMBOSIS POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DRUG ADMINISTRATION ERROR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EXCORIATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EXPOSURE TO TOXIC AGENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FOREIGN BODY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMATURIA TRAUMATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ILIOTIBIAL BAND SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IN-STENT ARTERIAL RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INCISION SITE PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LIMB TRAUMATIC AMPUTATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MENISCUS LESION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MULTIPLE FRACTURES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MULTIPLE INJURIES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MUSCLE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MUSCLE STRAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERIORBITAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PLAQUE SHIFT</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST CONCUSSION SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">POST PROCEDURAL STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC NECK SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ADHESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE FEVER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROCEDURAL DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROCEDURAL NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROCEDURAL VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FUME INHALATION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SCAPULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SEROMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SNAKE BITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPLENIC RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>STERNAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUTURE RELATED COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TENDON INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ULNA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VASCULAR ACCESS COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WOUND EVISCERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WOUND HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANGIOGRAM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTERIOGRAM CORONARY ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BIOPSY LUNG</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE MB INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD HOMOCYSTEINE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD IRON DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD MAGNESIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE ORTHOSTATIC ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE SYSTOLIC INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD TESTOSTERONE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD THYROID STIMULATING HORMONE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD TRIGLYCERIDES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD URIC ACID INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD URINE PRESENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BONE DENSITY ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BREATH SOUNDS ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC ENZYMES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC MURMUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC STRESS TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CAROTID BRUIT</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ECHOCARDIOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">ELECTROCARDIOGRAM CHANGE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST SEGMENT ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST SEGMENT ELEVATION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST-T CHANGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FEMORAL BRUIT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GLOMERULAR FILTRATION RATE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GLYCOSYLATED HAEMOGLOBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEART RATE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEART RATE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEART RATE IRREGULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HELICOBACTER TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LIPIDS ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>METABOLIC FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OCCULT BLOOD POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OXYGEN CONSUMPTION INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROSTATIC SPECIFIC ANTIGEN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RED BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RED BLOOD CELL SEDIMENTATION RATE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THYROID FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TROPONIN I INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TROPONIN T INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URINE LEUKOCYTE ESTERASE POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VITAMIN B12 DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VITAMIN D DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FLUID RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IMPAIRED FASTING GLUCOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LACTIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VITAMIN B COMPLEX DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VITAMIN D DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTHROFIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BONE LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CERVICAL SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHONDROCALCINOSIS PYROPHOSPHATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DUPUYTREN'S CONTRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EXOSTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FRACTURE NONUNION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>JOINT EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>JOINT STIFFNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LIMB DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">MUSCULOSKELETAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MYOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OSTEOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PAIN IN JAW</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERIARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PLANTAR FASCIITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POLYMYALGIA RHEUMATICA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SACROILIITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPONDYLOLISTHESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SYNOVIAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TENDINOUS CONTRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TENDONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TENOSYNOVITIS STENOSANS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRIGGER FINGER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VERTEBRAL FORAMINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACOUSTIC NEUROMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA STAGE IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BENIGN BREAST NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BENIGN OVARIAN TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLADDER NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BRAIN NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BREAST CANCER STAGE III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIFFUSE LARGE B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">GLIOBLASTOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMANGIOMA OF SPLEEN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEAD AND NECK CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEAD AND NECK CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOPHARYNGEAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LARYNGEAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LIP AND/OR ORAL CAVITY CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LIPOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MELANOCYTIC NAEVUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MENINGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>METASTASES TO LYMPH NODES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>METASTATIC MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>METASTATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NEURILEMMOMA MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OVARIAN EPITHELIAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL HAEMANGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SINONASAL PAPILLOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SKIN CANCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SKIN PAPILLOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER LIMITED STAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THYROID NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URETERIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UTERINE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VULVAL CANCER STAGE 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ALTERED STATE OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>AMNESIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARACHNOIDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATAXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BALANCE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BURNING SENSATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COGNITIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COMPLICATED MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CUBITAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIABETIC NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIZZINESS EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIZZINESS POSTURAL</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DYSAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ESSENTIAL TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>GUILLAIN-BARRE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">HEAD DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEAD TITUBATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HEMIPLEGIC MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOXIC-ISCHAEMIC ENCEPHALOPATHYv</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>IIIRD NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTENTION TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LACUNAR INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LATERAL MEDULLARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LUMBAR RADICULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MENTAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MYELOMALACIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NERVE COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NEUROLOGICAL SYMPTOM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NYSTAGMUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RADICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SENSORY DISTURBANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPEECH DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPONDYLITIC MYELOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUBDURAL HYGROMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THALAMIC INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THROMBOTIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRANSIENT GLOBAL AMNESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UNRESPONSIVE TO STIMULI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">URAEMIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VERTEBRAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AFFECTIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ALCOHOL ABUSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ALCOHOL PROBLEM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANXIETY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BIPOLAR I DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DELIRIUM TREMENS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DEPRESSED MOOD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DEPRESSION SUICIDAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, VISUAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OBSESSIVE-COMPULSIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>STRESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BLADDER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CYSTITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CYSTITIS INTERSTITIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERTONIC BLADDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MICROALBUMINURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NOCTURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POLLAKIURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URETHRAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URINARY HESITATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URINE FLOW DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BREAST CALCIFICATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BREAST MASS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BREAST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DYSFUNCTIONAL UTERINE BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EPIDIDYMAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FALLOPIAN TUBE CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FEMALE GENITAL TRACT FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMATOSPERMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PELVIC HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PENILE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POLYCYSTIC OVARIES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROSTATITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PROSTATOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SEXUAL DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPERMATOCELE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TESTICULAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BRONCHIAL HYPERREACTIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BRONCHITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHOKING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DYSPNOEA PAROXYSMAL NOCTURNAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERVENTILATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MEDIASTINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NASAL POLYPS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NASAL SEPTUM ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NON-CARDIOGENIC PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE AIRWAYS DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ORTHOPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ALKALOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THROAT TIGHTNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRACHEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>UPPER-AIRWAY COUGH SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACTINIC KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">DERMATITIS ATOPIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ECCHYMOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERKERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INCREASED TENDENCY TO BRUISE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LICHENOID KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LIVEDO RETICULARIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PRECANCEROUS SKIN LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PRURITUS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RASH GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RASH PRURITIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SWELLING FACE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CARDIAC ABLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC PACEMAKER BATTERY REPLACEMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CARDIAC PACEMAKER REPLACEMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CHOLECYSTECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>COLOSTOMY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DENTAL IMPLANTATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HIP ARTHROPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>KNEE ARTHROPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LEG AMPUTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE REMOVAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>NEPHRECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SINUS OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SPINAL FUSION SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THERAPY CESSATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">TONSILLECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TOOTH EXTRACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>TRANSURETHRAL PROSTATECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ACCELERATED HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>AORTIC INTRAMURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTERIAL SPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLEEDING VARICOSE VEIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE FLUCTUATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INADEQUATELY CONTROLLED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ILIAC ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ILIAC ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>LABILE HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>MALIGNANT HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PALLOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERIPHERAL COLDNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>POOR PERIPHERAL CIRCULATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>RAYNAUD'S PHENOMENON</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>REPERFUSION INJURY</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">SUBCLAVIAN ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN STEAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>VENOUS INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
              <event>
                <sub_title>WEGENER'S GRANULOMATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="686"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dana Haudek / Project Manager</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>928-925-4054</phone>
      <email>dana.haudek@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

